# CDC Vitamin D Standardization-Certification Program (VDSCP)

# Participation Evaluation Report 25-hydroxyvitamin D in serum (250HD)

Lab ID: LXX Data Collection Time Frame:

Date

Cycle: #

## **Mean Bias Evaluation Results**

Acceptable bias criteria is  $\pm 5.0\%$ .<sup>3</sup>

	Bias (%				
Mean	SD	95% ( Ii	Confidence nterval	Proportion of Samples Meeting Bias Criteria	Evaluation Result
-3.4	4.2	-4.8	-2.1	55%	WITHIN RANGE

## **Mean Imprecision Evaluation Results**

Acceptable imprecision criteria is  $\leq 10.0\%$ .<sup>3</sup>

	Imprecision			
Mean	SD	10th Pe	and 90th rcentile	Evaluation Result
3.8	1.4	1.8	6.0	WITHIN RANGE

## Certification Status: CERTIFIED

Information planned to be published on the CDC Website:

Please review the information to ensure it is correct and is how you would like to be represented on the CDC website as a standardized laboratory.

Douticinont	Measurement	Method	Measurement Range	Proportion of Samples	Participant contact	Certification
Participant	Principle	Identifier	(nmol/L)	Meeting Bias Criteria	information	Date
				55%		

<u>Contacts</u> : Standardization@cdc.gov

Hubert W Vesper (770)488-4191 HVesper@cdc.gov Julianne Cook Botelho (770)488-7391 JBotelho@cdc.gov

# DATA ANALYSIS FOR TOTAL 25(OH)D

#### Lab & Platform ID: LXX

The following report summarizes information on bias and imprecision of total 25-hydroxyvitamin D [25(OH)D] measurements performed as part of the VDSCP. Total 25-hydroxyvitamin D [25(OH)D] is defined as the sum of 25(OH)D2 and 25(OH)D3. The bias is the difference between the mean value reported for a sample by the participant and the reference value assigned to the sample.

The reference measurements were performed in Professor Dr. Linda Thienpont's Laboratory at the University of Ghent and at the Centers for Disease Control and Prevention by Mineva et al.<sup>1,2</sup> Reference values can be found in Appendix B of this report.

Method comparison and bias estimation were performed by the procedures described in CLSI document EP9-A2 "Method Comparison and Bias Estimation Using Patient Samples."<sup>3</sup> Linear regression analysis and difference plots were calculated using Analyze-It Software package (Version 2.21 Excel 12+). Findings on measurement bias and imprecision were compared against the suggested performance criteria for 25(OH)D of  $\pm$ 5.0 % bias and  $\leq$ 10.0 % for imprecision.<sup>4</sup>

The following pages include four graphs described in Section 4.2 of CLSI EP9-A2. Graphs B1 (sample mean) and B2 (individual values) are scatter plots with linear regression line and 95% prediction intervals. Graphs B3 (sample mean) and B4 (individual values) are bias plots showing the suggested bias criterion. Additional information on bias, imprecision and total error is provided, which is not part of the CLSI EP9-A2 protocol.

To be considered certified, a participant must meet criteria for bias and imprecision.

#### SUMMARY OF DATA POINTS RECEIVED BY PARTICIPANT for TOTAL 25(OH)D

Expected data points: 160

Sample Means: 40

Data points outside reportable range (3.03 - 225 nmol/L): 0

Data points not reported by participant: 0

Data points removed according to EP9-A2: 0

Please refer to Appendix A for a summary of all reported data.

#### References

(1) Stepman HC, Vanderroost A, Van Uytfanghe K, Thienpont LM. Candidate Reference Measurement Procedures for Serum 25hydroxyvitamin D3 and 25-hydroxyvitamin D2 by Using Isotope-Dilution Liquid Chromatography-Tandem Mass Spectrometry. Clin Chem. 2011; 57: 441-448.

(2) Mineva EM, Schleicher RL, Chaudhary-Webb M, Maw KL, Botelho JC, Vesper HW, Pfeiffer CM. A Candidate Reference Measurement Procedure for Quantifying Serum Concentrations of 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 Using Isotope-Dilution Liquid Chromatography-Tandem Mass Spectrometry. Analytical and Bioanalytical Chemistry. 2015; 407(19): 5615-5624.

(3) Clinical Laboratory Standards Institute. Method Comparison and Bias Estimation Using Patient Samples (CLSI document EP9-

A2). Wayne, PA: Clinical Laboratory Standards Institute. 2002.

(4) Stöckl D, Sluss PM, Thienpont LM. Clin Chim Acta 2009; 408: 8-13.

(5) Fraser CG. Biological variation: from principles to practice. Washington DC. AACC Press, 2001.

(6) Clinical Laboratory Standards Institute. CLSI document C37. Wayne, PA: Clinical Laboratory Standards Institute. 1999.

## LINEAR REGRESSION USING MEAN OF REPORTED VALUES

B1 in Section 4.2 CLSI EP9-A2

n	40				
R <sup>2</sup>	0.9882				
Term	Coefficient	959	% CI	SE	р
Term Intercept	Coefficient 1.7011	<b>95</b> 9 -1.0610	% <b>CI</b> 4.4631	<b>SE</b> 1.3644	<b>p</b> 0.2201



## LINEAR REGRESSION USING INDIVIDUAL REPORTED VALUES

B2 in Section 4.2 CLSI EP9-A2





## DIFFERENCE PLOT USING SAMPLE MEAN OF REPORTED VALUES

B3 in Section 4.2 CLSI EP9-A2





## **BIAS EVALUATION OF MEAN REPORTED VALUES (N=40)**

Acceptable bias criteria is ± 5.0%.4

## Overall Mean Bias on Mean of Reported Values Per Sample Data

For bias assessments, the mean of replicate measurements (n=4) was calculated for each sample and compared to the reference value. The mean bias was calculated from the individual sample biases of all 40 samples to determine the overall bias.

Mean	SD	95% Confi Interv	dence al	Min	Max	Evaluation Result of Mean Bias
-3.4	4.2	WITHIN RANGE				

### The following evaluations are provided for information only.

## Data Evaluation Using Subgroups on Mean Reported Values

(Section 6.3 in CLSI EP9)

			Bias (%)					
Subgroup	Reference Value Conc. Range (nmol/L)		Mean	SD	95% Confidenc	Min	Max	
1 (n=13)	24.0	63.2	-2.9	3.5	-4.8	-0.9	-8.0	5.3
2 (n=13)	63.4	75.1	-2.9	4.6	-5.4	-0.3	-9.8	7.0
3 (n=14)	75.9	220	-4.5	4.5	-7.0	-2.1	-11.2	7.8

The following evaluations are provided for information only.

Mean of Reported Results WITHIN RANGE of Bias Criterion

Assessment was made using mean values reported from 4 replicate measurements

	n	Reference Value Concentration Range (nmol/L)		Samples within suggested criterion (%)	
Group 1	13	24.0 63.2		62	
Group 2	13	63.4	75.1	62	
Group 3	14	75.9 220		43	
OVERALL	40	24.0 220		55	

## **BIAS EVALUATION OF MEAN REPORTED VALUES (N=40)- CON'T**

The following evaluations are provided for information only.

## Percent Difference Trend on Individual Samples Over Time

Dates:

Date # of Quarterly Challenges: #



## **IMPRECISION EVALUATION**

Acceptable imprecision criteria is  $\leq 10.0\%$ .<sup>4</sup> (Not part of EP9-A2)



## Overall Mean Imprecision of Reported Values

For imprecision assessments, the percent coefficient of variation (%CV) of the replicate measurements (n=4) was calculated for each sample. The mean imprecision was calculated from the %CV from all 40 samples to determine the overall imprecision.

Mean	SD	10th and Percent	90th tile	Min	Max	Evaluation Result of Mean Imprecision
3.8	1.4	1.8	6.0	1.2	7.0	WITHIN RANGE

## **IMPRECISION EVALUATION (CON'T)**

The following evaluations are provided for information only.

Acceptable imprecision is  $\leq 10.0\%$ .<sup>4</sup> (Not part of EP9-A2)

## Data Evaluation Using Subgroups

			Imprecision (%CV)					
Subgroup	Reference Value Conc. Range (nmol/L)		Mean	SD	10th - 90th P	ercentile	Min	Max
1 (n=13)	24.0	63.2	4.0	1.2	2.0	5.9	1.2	6.7
2 (n=13)	63.4	75.1	3.6	1.5	1.8	6.5	1.8	7.0
3 (n=14)	75.9	220	4.0	1.6	1.5	6.0	1.3	6.0

## Samples within Imprecision Criterion

Assessment was made using individual values reported over 2 days (n=4) for each sample.

	n	Reference Value Concentration Range (nmol/L)		Samples within suggested criterion (%)	
Group 1	13	24.0	63.2	100	
Group 2	13	63.4	75.1	100	
Group 3	14	75.9 220		100	
OVERALL	40	24.0	220	100	

## TOTAL ERROR ASSESSMENT USING INDIVIDUAL REPORTED VALUES

The following evaluations are provided for information only.

The suggested total error was calculated<sup>5</sup> as  $\pm$  21.5% based on the suggested bias and imprecision of  $\pm$  5.0% and  $\leq$  10.0%, respectively. (Not part of EP9-A2)



The following evaluations are provided for information only.

## Samples within Suggested Total Error Criterion

Assessment was made using the percent difference of individual values reported over 2 days.

	n	Reference Value Concentration Range (nmol/L)		Samples within suggested criterion (%)		
Group 1	53	24.0	63.2	100		
Group 2	53	63.4	75.1	100		
Group 3	54	75.9 220		100		
OVERALL	160	24.0	220	100		

## **APPENDIX A: REPORTED VALUES**

		Shipment					
Sample #	Phase	Date		Day 1	Day 2	2	Overall Mean
1	2	Date	57.7	58.7	57.6	62.6	59.1
2	2	Date	27.6	27.8	30.2	27.5	28.2
3	2	Date	68.2	71.6	75.1	69.9	71.2
4	2	Date	84.5	91.9	97.8	89.9	91.0
5	2	Date	117	113	119	123	118
6	2	Date	83.9	81.9	93.4	83.9	85.7
7	2	Date	53.2	49.6	50.2	54.2	51.8
8	2	Date	65.4	62.6	63.8	64.0	63.9
9	2	Date	76.9	78.7	75.4	76.1	76.8
10	2	Date	62.2	64.6	62.5	62.4	62.9
11	2	Date	24.4	22.5	24.1	24.1	23.7
12	2	Date	105	109	118	104	109
13	2	Date	97.8	98.1	91.7	90.2	94.4
14	2	Date	68.4	65.2	64.8	64.3	65.7
15	2	Date	80.2	77.0	85.8	86.5	82.4
16	2	Date	69.5	69.2	73.4	72.0	71.0
17	2	Date	35.7	33.1	35.8	32.9	34.3
18	2	Date	62.5	62.1	69.8	63.6	64.5
19	2	Date	106	105	109	112	108
20	2	Date	45.6	48.9	50.7	48.1	48.3
21	2	Date	48.1	44.8	48.2	48.5	47.4
22	2	Date	63.8	65.2	72.3	61.6	65.7
23	2	Date	71.8	76.0	74.2	71.0	73.2
24	2	Date	75.1	74.9	70.8	71.7	73.1
25	2	Date	89.9	87.5	89.8	89.4	89.1
26	2	Date	76.9	77.1	74.0	76.5	76.1
27	2	Date	50.0	51.4	49.5	47.4	49.6
28	2	Date	198	201	225	208	208
29	2	Date	65.9	64.2	59.9	61.4	62.8
30	2	Date	55.6	56.3	64.2	60.3	59.1
31	2	Date	58.4	57.3	60.9	60.3	59.2
32	2	Date	71.1	69.8	68.4	66.3	68.9
33	2	Date	53.4	58.1	54.8	53.0	54.8
34	2	Date	68.7	72.4	72.3	76.4	72.4
35	2	Date	51.7	49.7	53.3	54.3	52.2
36	2	Date	62.9	62.2	59.6	58.4	60.7
37	2	Date	52.5	51.2	51.2	51.3	51.5
38	2	Date	112	108	113	115	112
39	2	Date	63.3	61.5	66.3	66.5	64.4
40	2	Date	84.1	85.2	84.7	77.9	83.0

# CDC VDSCP

#### Participant Evaluation Report

#### **APPENDIX B: REFERENCE VALUES**

- All materials are non-pooled human sera from single donors obtained following the CLSI C37-A protocol.<sup>6</sup>
- Concentrations were assigned by Professor Dr. Linda Thienpont at the University of Ghent by ID-LC-MS/MS and Mineva et al. at the Centers for Disease • Control and Prevention by ID-LC-MS/MS.<sup>1,2</sup>
- 25(OH)D<sub>3</sub> and 25(OH)D<sub>2</sub> concentrations are reference values, but Epi-25(OH)D<sub>3</sub> concentrations should only be considered as target values.
- Only Total 25(OH)D will be used in Phase 2 Certification to evaluate platforms. Concentrations for 25(OH)D<sub>3</sub>, 25(OH)D<sub>2</sub>, and epi-25(OH)D<sub>3</sub> are provided

		<loq (1.50="" l)<="" nmol="" td=""><td></td><td></td><td></td><td></td></loq>						
25(OH)D <sub>3</sub>		25-hydroxyvitamin D3						
25(OH)D		25-hydroxyvitamin D2						
25(0H)D		Total 25-hydroxyyitamin D						
		C 2 opimor 25 hydroxyvitamin D2			_			
Epi-25		C-3 epin	ier 25-nyuroxyv	ntamin D3				
Г		Reference Values			Τ		Target	Values
							Epi-25(	OH)D₃
						n	mol/L	%CV
PS01		1.4	<loq< td=""><td></td><td></td><td></td><td>5.02</td><td>4.0</td></loq<>				5.02	4.0
PS02		2.9	1.02.02	4.5			<loq< td=""><td></td></loq<>	
PS03		1.3	<100				4.09	2.2
PS04		0.6	<100			_	8.91	2.9
PS05		0.5	<100			_	10.4	9.6
P300		1.0	<luq 21.000</luq 				0.09	7.4
PS07		0.1	2100				2 25	1.9
P 508		1.5	~~~~~~	1 1			2.35	1.9
PS10		1.1		17		-	2.80	0.0
PS11		1.2	<100	1.7		-	<100	0.1
PS12		0.7	" her har "hady	7.0		-	10.5	15
PS13		0.3	<100	7.0			6.59	0.1
PS14		1.8		2.1			4.24	3.6
PS15		1.3		0.5			7.37	4.3
PS16		1.5		2.8			4.53	6.6
PS17		1.5		1.3			1.98	9.6
PS18		1.8	<loq< td=""><td></td><td></td><td></td><td>9.72</td><td>12.6</td></loq<>				9.72	12.6
PS19		1.3	<loq< td=""><td></td><td></td><td></td><td>9.93</td><td>7.9</td></loq<>				9.93	7.9
PS20		0.9		1.3			3.18	2.3
PS21		0.5	<loq< td=""><td></td><td></td><td></td><td>2.42</td><td>5.5</td></loq<>				2.42	5.5
PS22		1.1	<100				3.77	15.1
PS23		1.6	<loq< td=""><td></td><td></td><td></td><td>3.39</td><td>0.0</td></loq<>				3.39	0.0
PS24		1.7	<loq< td=""><td></td><td></td><td></td><td>3.37</td><td>3.8</td></loq<>				3.37	3.8
PS25		0.3		3.2			4.87	12.5
PS26		2.0		0.4			2.92	0.1
PS27		2.3	400	2.3		-	1.//	0.1
PS28		0.7	<luq< td=""><td><u> </u></td><td></td><td>_</td><td>48.Z</td><td>5.9</td></luq<>	<u> </u>		_	48.Z	5.9
P329		1.0		0.4			2.24	2.0
P 3 5 U		1.0		2.9		_	3.30	5.0
P\$331		1.0	2100	2.0			4.30	0.1
PS32		0.9	~~~~~~	2.4		-	3.05	0.1
PS34		1.4	<100	2.7			4.73	16.0
PS35		0.3	<100				3.05	17.3
P\$36		1.9	<100				2.00	0.1
PS37		1.0		2.6		┫ ⊢	2.23	14.2
PS38		0.8	<100			┫ ⊢	6.71	0.0
PS39		1.1		1.8			4.68	3.6
PS40		0.6	<loq_< td=""><td>-</td><td></td><td>1 –</td><td>5.22</td><td>8.2</td></loq_<>	-		1 –	5.22	8.2

(1) Stepman HC, Vanderroost A, Van Uytfanghe K, Thienpont LM. Candidate Reference Measurement Procedures for Serum 25-hydroxyvitamin D3 and 25-

hydroxyvitamin D2 by Using Isotope-Dilution Liquid Chromatography-Tandem Mass Spectrometry. Clin Chem. 2011; 57: 441-448.

(2) Mineva EM, Schleicher RL, Chaudhary-Webb M, Maw KL, Botelho JC, Vesper HW, Pfeiffer CM. A Candidate Reference Measurement Procedure for Quantifying Serum Concentrations of 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 Using Isotope-Dilution Liquid Chromatography-Tandem Mass Spectrometry. Analytical and Bioanalytical Chemistry. 2015; 407(19): 5615-5624.

(6) Clinical Laboratory Standards Institutes (CLSI C37-A). Wayne, PA: Clinical Laboratory Standards Institute. 1999.